VIRI News and Press, Virios Therapeutics Inc. From 08/10/22

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia , today announced that Greg Duncan, Chairman and CEO of Virios Ther...

Company's September Phase 2b trial results could be transformative for fibromyalgia patients New York, New York--(Newsfile Corp. - August 8, 2022) - PCG Digital -- Life may change for the better for the 10 million Americans suffering from fibromyalgia. The development-stage biotech Virios The...

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia , announced today that its second quarter 2022 financial results wi...

Armed with near-term catalyst, VIRI is poised for next growth stage New York, New York--(Newsfile Corp. - July 26, 2022) - PCG Digital -- Development-stage biotechnology company Virios Therapeutics (NASDAQ: VIRI) is working to advance a new therapeutic approach, one that is focused on addre...

New York, New York--(Newsfile Corp. - July 19, 2022) - PCG Digital -- With the aim of improving the standard of care for the 10 million Americans living with fibromyalgia ("FM"), Virios Therapeutics (NASDAQ: VIRI) anticipates Phase 2b results for its lead treatment candidate, oral IMC-1, in Se...

Study Demonstrates Potential Utility of Combination Antiviral Drug Therapies, to Treat Patients with Chronic Illnesses such as Fibromyalgia and Irritable Bowel Syndrome Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on ad...

Virios Therapeutics, Inc. (VIRI) Q1 2022 Earnings Conference Call May 12, 2022 8:30 a.m. ET Company Participants Angela Walsh - Senior Vice President of Finance, and Treasurer Greg Duncan - Chief Executive Officer Ralph Grosswald - Senior Vice President of Operations Conference Call Participa...

Virios Therapeutics press release (NASDAQ:VIRI): Q1 GAAP EPS of -$0.48. As of March 31, 2022, Virios Therapeutics’ cash totaled $11.4 million. The Company believes it will have sufficient resources to fund its planned operations through the end of 2022. For further details see: V...

- Enrollment Completed in FORTRESS Study with Top Line Data Expected in September 2022 - - Conference Call Today at 8:30 a.m. ET - Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antivira...

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia , announced today that its first quarter 2022 financial results wil...